Date:6/7/2011

looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating MDS, whether Telintra treatment results in hematologic improvement in patients with MDS or offers an alternative to RBC blood transfusions, the use of Telintra in Revlimid refractory or resistant patients, the use of Telintra in the treatment of SCIN, and the use of Telcyta for the treatment of cancer. These forward-looking statements are based upon Telik's current expectations and there are important factors that could cause actual results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ending December 31, 2010. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

'/>"/>

SOURCE Telik, Inc. Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Telik Announces Financial Results For 2008 Second Quarter
2. ReceptorBio Announces Diabetes License Agreement With Telik
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. Telik Announces Receipt of Nasdaq Notice
5. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
6. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces New TRAP Drug Discovery Agreement
9. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
10. Telik Reports Preclinical Results at AACR Annual Meeting
11. Telik Announces Second Quarter 2009 Financial Results